Vedolizumab in Early and Late Crohn's Disease (LOVE‐CD): A Phase 4 Open‐Label Cohort Study
JCC Plus · 2026-05 · 1 (3)
DOI: 10.1002/jcc5.70038 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift JCC Plus, online erschienen am 21.05.2026. Verfasst von Catarina Costa. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The LOVE‐CD study emerged from the growing focus on early intervention in Crohn's disease and the lack of prospective evidence evaluating how disease duration affects vedolizumab efficacy.
Methods
LOVE‐CD was a phase 4, open‐label cohort study including 260 patients with moderate‐to‐severe CD, where patients were stratified into early (≤ 2 years since diagnosis) and late (> 2 years) disease groups. Vedolizumab was administered over 52 weeks following standard induction and maintenance dosing. The primary endpoint was combined clinical and endoscopic remission at weeks 26 and 52. Secondary outcomes included endoscopic response, absence of ulcers, histological remission, and corticosteroid‐free clinical remission. Key Findings The primary endpoint was achieved more frequently in early CD compared to late CD (31.4% vs. 8.6%). Early CD patients also showed higher rates of ulcer absence, endoscopic response, sustained clinical response, histological improvements and corticosteroid‐free remission. Serious adverse events and hospitalizations were more common in late CD. Dose intensification was more commonly required in early CD and increased drug concentrations but did not improve endoscopic remission in non‐responders.
Discussion
These findings support the benefit of early biologic intervention, potentially reflecting lower cumulative bowel damage and less prior biologic exposure in patients with short disease duration. However, baseline differences between groups, including prior anti‐TNF use and disease complexity, may limit interpretation. Additionally, cost‐effectiveness considerations may impact treatment positioning.
Conclusion
The LOVE‐CD study provides prospective evidence supporting early vedolizumab use in CD. Further randomized studies are needed to define optimal treatment sequencing and incorporate patient‐centered and economic factors into clinical decision‐making.
Zitieren
APA
Costa, C. (2026). Vedolizumab in Early and Late Crohn's Disease (LOVE‐CD): A Phase 4 Open‐Label Cohort Study. JCC Plus, 1(3). https://doi.org/10.1002/jcc5.70038
Vancouver
Costa C. Vedolizumab in Early and Late Crohn's Disease (LOVE‐CD): A Phase 4 Open‐Label Cohort Study. JCC Plus. 2026;1(3). doi:10.1002/jcc5.70038
BibTeX
@article{Costa2026,
author = {Costa, Catarina},
title = {Vedolizumab in Early and Late Crohn's Disease (LOVE‐CD): A Phase 4 Open‐Label Cohort Study},
journal = {JCC Plus},
year = {2026},
volume = {1},
number = {3},
doi = {10.1002/jcc5.70038}
}
EUVIMED